OpenLB
Open Library of Bioscience
Advanced Search
Nutrients
Apr 29, 2022;14 (9):

Monotropein Improves Dexamethasone-Induced Muscle Atrophy via the AKT/mTOR/FOXO3a Signaling Pathways.

Piao Wang, Seok Yong Kang, Su Jin Kim, Yong-Ki Park, Hyo Won Jung
Author Information
  1. Piao Wang: Department of Herbology, College of Korean Medicine, Dongguk University, Gyeongju 38066, Korea. ORCID
  2. Seok Yong Kang: Korean Medicine R&D Center, Dongguk University, Gyeongju 38066, Korea.
  3. Su Jin Kim: Department of Anesthesiology and Pain Medicine, College of Medicine, Dongguk University, Gyeongju 38066, Korea.
  4. Yong-Ki Park: Department of Herbology, College of Korean Medicine, Dongguk University, Gyeongju 38066, Korea.
  5. Hyo Won Jung: Department of Herbology, College of Korean Medicine, Dongguk University, Gyeongju 38066, Korea.
PMID: 35565825 DOI: 10.3390/nu14091859

Abstract

The present study aimed to investigate the effects of monotropein (MON) on improving dexamethasone (DEX)-induced muscle atrophy in mice and C2C12 mouse skeletal muscle cells. The body weights, grip strengths, and muscle weights of mice were assessed. The histological change in the gastrocnemius tissues was also observed through H&E staining. The expression of myosin heavy chain (MyHC), muscle ring finger 1 (MuRF1), and muscle atrophy F-box (Atrogin1) and the phosphorylation of AKT, mTOR, and FOXO3a in the muscle tissues of mice and C2C12 myotubes were analyzed using Western blotting. MON improved muscle atrophy in mice and C2C12 myotubes by regulating catabolic states via the AKT/mTOR/FOXO3a signaling pathways, and enhanced muscle function by the increases of muscle mass and strength in mice. This suggests that MON could be used for the prevention and treatment of muscle atrophy in patients.

Keywords

AKT/mTOR/FOXO3a signaling pathways Atrogin1 MuRF1 dexamethasone monotropein muscle atrophy

References

  1. ACS Omega. 2021 Oct 11;6(41):26959-26968 [PMID: 34693116]
  2. J Physiol Sci. 2020 Sep 16;70(1):40 [PMID: 32938372]
  3. Mol Cell. 2004 May 7;14(3):395-403 [PMID: 15125842]
  4. J Cell Mol Med. 2018 Mar;22(3):1583-1600 [PMID: 29278309]
  5. Int J Mol Sci. 2014 Jun 20;15(6):11126-41 [PMID: 24955790]
  6. Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15790-7 [PMID: 26669439]
  7. Biochem Biophys Rep. 2019 Feb 11;18:100618 [PMID: 30805562]
  8. Biol Pharm Bull. 2005 Oct;28(10):1915-8 [PMID: 16204945]
  9. Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14440-5 [PMID: 11717410]
  10. Nature. 1997 May 1;387(6628):83-90 [PMID: 9139826]
  11. J Cachexia Sarcopenia Muscle. 2019 Apr;10(2):429-444 [PMID: 30793539]
  12. Cell Metab. 2015 Feb 3;21(2):237-248 [PMID: 25651178]
  13. J Spinal Cord Med. 2006;29(5):489-500 [PMID: 17274487]
  14. PLoS One. 2015 Jun 08;10(6):e0128263 [PMID: 26053620]
  15. Int J Biochem Cell Biol. 2013 Oct;45(10):2163-72 [PMID: 23806868]
  16. FEBS J. 2013 Sep;280(17):4294-314 [PMID: 23517348]
  17. Life Sci. 2009 May 8;84(19-20):637-40 [PMID: 19233212]
  18. Mol Nutr Food Res. 2018 May;62(9):e1700941 [PMID: 29578301]
  19. Am J Physiol Endocrinol Metab. 2001 Apr;280(4):E570-5 [PMID: 11254463]
  20. Int Immunopharmacol. 2014 Apr;19(2):206-13 [PMID: 24534773]
  21. Molecules. 2020 Jul 17;25(14): [PMID: 32709024]
  22. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9306-11 [PMID: 11459935]
  23. Am J Physiol Regul Integr Comp Physiol. 2010 Dec;299(6):R1572-81 [PMID: 20861279]
  24. Ageing Res Rev. 2010 Oct;9(4):369-83 [PMID: 20438881]
  25. Res Vet Sci. 2013 Feb;94(1):84-9 [PMID: 22939086]
  26. Front Physiol. 2013 Oct 11;4:284 [PMID: 24130531]
  27. Nat Cell Biol. 2001 Nov;3(11):1014-9 [PMID: 11715023]
  28. Int J Biochem Cell Biol. 2013 Oct;45(10):2121-9 [PMID: 23665154]
  29. Cell Metab. 2007 Dec;6(6):472-83 [PMID: 18054316]
  30. Free Radic Biol Med. 2016 Sep;98:218-230 [PMID: 26738803]
  31. J Pharm Biomed Anal. 2019 Mar 20;166:336-346 [PMID: 30690247]
  32. Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1128-36 [PMID: 11701425]
  33. Food Chem Toxicol. 2013 Mar;53:263-71 [PMID: 23261679]
  34. Cell Mol Life Sci. 2014 Nov;71(22):4361-71 [PMID: 25080109]
  35. Science. 2001 Nov 23;294(5547):1704-8 [PMID: 11679633]
  36. Am J Physiol. 1992 Jun;262(6 Pt 1):C1471-7 [PMID: 1616011]
  37. Int Immunopharmacol. 2014 Dec;23(2):575-80 [PMID: 25466264]
  38. PLoS One. 2012;7(12):e52363 [PMID: 23300651]
  39. Int J Biochem Cell Biol. 2005 Oct;37(10):1985-96 [PMID: 16125108]
  40. Biochem Biophys Res Commun. 2012 Jan 6;417(1):528-33 [PMID: 22166204]
  41. J Cell Physiol. 2002 Feb;190(2):170-9 [PMID: 11807821]
  42. Cell Metab. 2008 Nov;8(5):411-24 [PMID: 19046572]
  43. J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):648-661 [PMID: 34741441]

Grants

  1. 2021R1A2C1012267/National Research Foundation of Korea

MeSH Term

Dexamethasone
Humans
Iridoids
Muscle Fibers, Skeletal
Muscle, Skeletal
Muscular Atrophy
Proto-Oncogene Proteins c-akt
Signal Transduction
TOR Serine-Threonine Kinases
Ubiquitin-Protein Ligases

Chemicals

Iridoids
monotropein
Dexamethasone
Ubiquitin-Protein Ligases
MTOR protein, human
Proto-Oncogene Proteins c-akt
TOR Serine-Threonine Kinases
Journal Article
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0muscleatrophymiceMONC2C12AKT/mTOR/FOXO3amonotropeindexamethasoneweightstissuesMuRF1Atrogin1myotubesviasignalingpathwayspresentstudyaimedinvestigateeffectsimprovingDEX-inducedmouseskeletalcellsbodygripstrengthsassessedhistologicalchangegastrocnemiusalsoobservedH&EstainingexpressionmyosinheavychainMyHCringfinger1F-boxphosphorylationAKTmTORFOXO3aanalyzedusingWesternblottingimprovedregulatingcatabolicstatesenhancedfunctionincreasesmassstrengthsuggestsusedpreventiontreatmentpatientsMonotropeinImprovesDexamethasone-InducedMuscleAtrophySignalingPathways

Similar Articles

Cited By